This clinical trial is focused on studying a type of prostate cancer known as oligometastatic prostate cancer, which is a form of cancer that has spread to a limited number of other parts of the body. The study is investigating the effects of a treatment called lutetium (177Lu) vipivotide tetraxetan, also known by its code name AAA617. This treatment is compared to simply observing the patients without any active treatment to see if it can delay the return of the disease or the need for further treatment.

The trial involves adult male patients who have prostate cancer that shows positive results for a specific marker called prostate-specific membrane antigen (PSMA). The study uses a special type of imaging called Positron Emission Tomography (PET) to identify the presence of PSMA in the cancer. Patients will receive either the treatment or be placed under observation, and their progress will be monitored over time to see how the treatment affects the spread of cancer.

Participants in the study will undergo regular imaging tests, such as CT or MRI scans, to track the presence of cancer in the body. The main goal is to determine how long patients can remain free from new cancer growth or the need for additional treatment. The study will also look at other factors, such as the time it takes for the cancer to progress and the overall health and quality of life of the participants. The trial is expected to continue until 2030, with recruitment starting in 2024.